

Datasheet: HCA452

**BATCH NUMBER 173701**

<b>Description:</b>	HUMAN ANTI NIRSEVIMAB
<b>Specificity:</b>	NIRSEVIMAB
<b>Other names:</b>	Beyfortus
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD64626ia
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A
<b>Source</b>	HKB-11
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml
<b>Immunogen</b>	Nirsevimab

**Specificity**

**Human Anti-Nirsevimab Antibody, clone AbD64626ia** is a paratope specific, inhibitory, anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug nirsevimab, and its biosimilar products. It does not recognize the free Fusion glycoprotein F0 of RSV, nor nirsevimab in complex with Fusion glycoprotein F0 of RSV.

HCA452 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 2.7nM and is one of the three antibodies offered for ADA assays. Antibody [HCA450](#) has an affinity of 0.1nM and [HCA451](#) has an affinity of 0.5nM.

Nirsevimab (trade name Beyfortus) is a humanized monoclonal antibody of the IgG1/kappa isotype that targets the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process and neutralises several RSV A and B strains. Nirsevimab is indicated to treat respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.

[View a summary of all anti-nirsevimab antibodies](#)

---

**Affinity**

The monovalent intrinsic affinity of Human anti-Nirsevimab Antibody, clone AbD64626ia was measured as  $K_D = 2.7$  nM by real time, label-free molecular interaction analysis on immobilized nirsevimab.

---

**ELISA**

Clone AbD64626ia can be used in indirect ELISA to detect nirsevimab. It can also be used as a surrogate positive control or a calibrator in an anti-drug antibody (ADA) assay, together with [HCA450](#) and [HCA451](#).

Protocol: [ADA bridging ELISA](#)

---

**Storage**

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

**Guarantee**

12 months from date of despatch

---

**Acknowledgements**

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See [bio-rad.com/en-us/trademarks](http://bio-rad.com/en-us/trademarks) for details.

Beyfortus is a registered trademark of Sanofi, and AstraZeneca.

---

**Health And Safety Information**

Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/HCA452>

---

**Licensed Use**

For *in vitro*. research purposes and for commercial applications for the provision of in vitro

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

---

## Related Products

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI NIRSEVIMAB \(TZA0148\)](#)

[HUMAN ANTI NIRSEVIMAB:HRP \(TZA0148P\)](#)

[HUMAN ANTI NIRSEVIMAB \(TZA0147\)](#)

[HUMAN ANTI NIRSEVIMAB \(HCA450\)](#)

[HUMAN ANTI NIRSEVIMAB \(HCA451\)](#)

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)

'M450997:260619'

**Printed on 19 Jun 2026**

---

© 2026 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)